1,000
Participants
Start Date
July 13, 2017
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Blood draw
Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
Existing samples
Control DNA samples will be used that have been previously acquired in other studies.
RECRUITING
Vestre Viken Health Trust, Oslo, Drammen
RECRUITING
Danish National Epilepsy Centre, Dianalund
COMPLETED
Mount Sinai-Beth Israel Medical Center, New York
COMPLETED
St Luke's Roosevelt Hospital, New York
RECRUITING
Tallinn Children's Hospital, Tallinn
COMPLETED
Nationwide Children's Hospital, Columbus
RECRUITING
University Robert Debré, Paris
RECRUITING
Hospital for Sick Kids, Toronto
RECRUITING
Charles University, Prague
RECRUITING
Commissione Genetica Lega Italiana contro l'Epilepssia, Roma
RECRUITING
Walton Centre for Neurology and Neurosurgery, Liverpool
RECRUITING
Royal London Hospital, London
RECRUITING
St Thomas' Hospital, London
RECRUITING
King's College Hospital NHS Trust, London
RECRUITING
Swansea University, Swansea
King's College Hospital NHS Trust
OTHER
Charles University, Czech Republic
OTHER
Hopital Universitaire Robert-Debre
OTHER
Vestre Viken Hospital Trust
OTHER
The Hospital for Sick Children
OTHER
Cardiff University
OTHER
Odense University Hospital
OTHER
King's College London
OTHER